Abiraterone
The serum concentration of Lansoprazole can be increased when it is combined with Abiraterone.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Lansoprazole.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Lansoprazole.
Advertisement
Alendronate
The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole.
Alendronic acid
The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole.
Amiodarone
The metabolism of Lansoprazole can be decreased when combined with Amiodarone.
Advertisement
Amodiaquine
The serum concentration of Amodiaquine can be increased when it is combined with Lansoprazole.
Amphetamine
Lansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Anhydrous Tacrolimus
The serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole.
Advertisement
Apalutamide
The serum concentration of Lansoprazole can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Lansoprazole can be increased when it is combined with Aprepitant.
Aripiprazole
The serum concentration of Aripiprazole can be decreased when it is combined with Lansoprazole.
Armodafinil
The metabolism of Lansoprazole can be decreased when combined with Armodafinil.
Atazanavir
Lansoprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Atomoxetine
The metabolism of Lansoprazole can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Lansoprazole is combined with Atorvastatin.
Boceprevir
The metabolism of Lansoprazole can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Lansoprazole can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Lansoprazole can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Lansoprazole.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Lansoprazole.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Lansoprazole.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lansoprazole.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Lansoprazole.
Capecitabine
The metabolism of Lansoprazole can be decreased when combined with Capecitabine.
Carbamazepine
The metabolism of Lansoprazole can be increased when combined with Carbamazepine.
Cefditoren
The serum concentration of Cefditoren can be decreased when it is combined with Lansoprazole.
Celecoxib
The metabolism of Lansoprazole can be decreased when combined with Celecoxib.
Ceritinib
The serum concentration of Lansoprazole can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Lansoprazole.
Chloramphenicol
The metabolism of Lansoprazole can be decreased when combined with Chloramphenicol.
Cholecalciferol
The metabolism of Lansoprazole can be decreased when combined with Cholecalciferol.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Lansoprazole.
Cimetidine
The metabolism of Lansoprazole can be decreased when combined with Cimetidine.
Citalopram
The metabolism of Lansoprazole can be decreased when combined with Citalopram.
Clarithromycin
The metabolism of Lansoprazole can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Lansoprazole can be decreased when combined with Clemastine.
Clodronic Acid
The therapeutic efficacy of Clodronic Acid can be decreased when used in combination with Lansoprazole.
Clofezone
The metabolism of Lansoprazole can be decreased when combined with Rabeprazole.
Clopidogrel
The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Lansoprazole resulting in a loss in efficacy.
Clotrimazole
The metabolism of Lansoprazole can be decreased when combined with Clotrimazole.
Cobicistat
The metabolism of Lansoprazole can be decreased when combined with Cobicistat.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Lansoprazole.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Lansoprazole.
Crisaborole
The metabolism of Lansoprazole can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Lansoprazole can be decreased when combined with Crizotinib.
Cyclosporine
The metabolism of Lansoprazole can be decreased when combined with Cyclosporine.
Cysteamine
The therapeutic efficacy of Cysteamine can be decreased when used in combination with Lansoprazole.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lansoprazole.
Dabrafenib
The serum concentration of Lansoprazole can be decreased when it is combined with Dabrafenib.
Darunavir
The metabolism of Lansoprazole can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Dasatinib can be decreased when it is combined with Lansoprazole.
Dasatinib Anhydrous
The serum concentration of Dasatinib can be decreased when it is combined with Lansoprazole.
Deferasirox
The serum concentration of Lansoprazole can be decreased when it is combined with Deferasirox.
Delavirdine
The serum concentration of Delavirdine can be decreased when it is combined with Lansoprazole.
Dexmethylphenidate
Lansoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Dextroamphetamine
Lansoprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Dicumarol
The serum concentration of Dicoumarol can be increased when it is combined with Lansoprazole.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lansoprazole.
Diltiazem
The metabolism of Lansoprazole can be decreased when combined with Diltiazem.
Dothiepin
The metabolism of Lansoprazole can be decreased when combined with Dosulepin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Lansoprazole.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Lansoprazole.
Doxycycline
The metabolism of Lansoprazole can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Lansoprazole can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Lansoprazole can be decreased when combined with Dronedarone.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Lansoprazole.
Efavirenz
The metabolism of Lansoprazole can be decreased when combined with Efavirenz.
Enzalutamide
The serum concentration of Lansoprazole can be decreased when it is combined with Enzalutamide.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Lansoprazole.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Lansoprazole.
Erlotinib
The serum concentration of Erlotinib can be decreased when it is combined with Lansoprazole.
Erythromycin
The metabolism of Lansoprazole can be decreased when combined with Erythromycin.
Eslicarbazepine Acetate
The metabolism of Lansoprazole can be decreased when combined with Eslicarbazepine acetate.
Esomeprazole
The metabolism of Lansoprazole can be decreased when combined with Esomeprazole.
Etidronate
The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Lansoprazole.
Etidronic Acid
The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Lansoprazole.
Etravirine
The metabolism of Lansoprazole can be decreased when combined with Etravirine.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Lansoprazole.
Felodipine
The metabolism of Lansoprazole can be decreased when combined with Felodipine.
Ferric Carboxymaltose
Lansoprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric Pyrophosphate
Lansoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lansoprazole.
Floxuridine
The metabolism of Lansoprazole can be decreased when combined with Floxuridine.
Fluconazole
The serum concentration of Lansoprazole can be increased when it is combined with Fluconazole.
Fluindione
The serum concentration of Fluindione can be increased when it is combined with Lansoprazole.
Fluorouracil
The metabolism of Lansoprazole can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Lansoprazole can be decreased when combined with Fluoxetine.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Lansoprazole.
Fluvoxamine
The metabolism of Lansoprazole can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Lansoprazole can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Lansoprazole can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Lansoprazole can be increased when combined with Fosphenytoin.
Fusidate
The serum concentration of Lansoprazole can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Lansoprazole can be increased when it is combined with Fusidic Acid.
Gefitinib
The serum concentration of Gefitinib can be decreased when it is combined with Lansoprazole.
Gemfibrozil
The metabolism of Lansoprazole can be decreased when combined with Gemfibrozil.
Hypoxis hemerocallidea root extract
The serum concentration of Lansoprazole can be decreased when it is combined with St. John's Wort.
Ibandronate
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.
Ibandronic Acid
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Lansoprazole.
Idelalisib
The metabolism of Lansoprazole can be decreased when combined with Idelalisib.
Imatinib
Lansoprazole may increase the dermatologic adverse activities of Imatinib.
Indinavir
The serum concentration of Indinavir can be decreased when it is combined with Lansoprazole.
INDINAVIR ANHYDROUS
The serum concentration of Indinavir can be decreased when it is combined with Lansoprazole.
Irbesartan
The metabolism of Lansoprazole can be decreased when combined with Irbesartan.
Iron
Lansoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Carbonyl
Lansoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Sucrose
Lansoprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron-Dextran Complex
Lansoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isavuconazole
The serum concentration of Lansoprazole can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Lansoprazole can be decreased when combined with Isavuconazonium.
Isoniazid
The metabolism of Lansoprazole can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Lansoprazole can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Itraconazole can be decreased when it is combined with Lansoprazole.
Ivacaftor
The serum concentration of Lansoprazole can be increased when it is combined with Ivacaftor.
Ketoconazole
The serum concentration of Ketoconazole can be decreased when it is combined with Lansoprazole.
Lapatinib
The metabolism of Lansoprazole can be decreased when combined with Lapatinib.
Ledipasvir
The serum concentration of Ledipasvir can be decreased when it is combined with Lansoprazole.
Leflunomide
The metabolism of Lansoprazole can be decreased when combined with Leflunomide.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Lansoprazole.
Lopinavir
The metabolism of Lansoprazole can be decreased when combined with Lopinavir.
Losartan
The metabolism of Lansoprazole can be decreased when combined with Losartan.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Lansoprazole.
Luliconazole
The serum concentration of Lansoprazole can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Lansoprazole can be increased when it is combined with Lumacaftor.
Manidipine
The metabolism of Lansoprazole can be decreased when combined with Manidipine.
Medronate
The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Lansoprazole.
Mesalamine
The therapeutic efficacy of Mesalazine can be decreased when used in combination with Lansoprazole.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Lansoprazole.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Lansoprazole.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lansoprazole.
Methylphenidate
Lansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Lansoprazole.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Lansoprazole.
Midostaurin
The metabolism of Lansoprazole can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Lansoprazole can be increased when it is combined with Mifepristone.
Mitotane
The serum concentration of Lansoprazole can be decreased when it is combined with Mitotane.
Moclobemide
The metabolism of Lansoprazole can be decreased when combined with Moclobemide.
Modafinil
The metabolism of Lansoprazole can be decreased when combined with Modafinil.
MYCOPHENOLATE
The serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole.
Mycophenolic Acid
The serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Lansoprazole.
Nefazodone
The metabolism of Lansoprazole can be decreased when combined with Nefazodone.
Nelfinavir
The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Lansoprazole resulting in a loss in efficacy.
Netupitant
The serum concentration of Lansoprazole can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Lansoprazole can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Lansoprazole can be decreased when combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Lansoprazole.
Nilotinib
The serum concentration of Nilotinib can be decreased when it is combined with Lansoprazole.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Lansoprazole.
Olaparib
The metabolism of Lansoprazole can be decreased when combined with Olaparib.
Omeprazole
The metabolism of Lansoprazole can be decreased when combined with Omeprazole.
Osimertinib
The serum concentration of Lansoprazole can be increased when it is combined with Osimertinib.
Palbociclib
The serum concentration of Lansoprazole can be increased when it is combined with Palbociclib.
Pamidronate
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Lansoprazole.
Pamidronic Acid
The therapeutic efficacy of Pamidronate can be decreased when used in combination with Lansoprazole.
Pantoprazole
The metabolism of Lansoprazole can be decreased when combined with Pantoprazole.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Lansoprazole.
Pentobarbital
The metabolism of Lansoprazole can be increased when combined with Pentobarbital.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Lansoprazole.
Phenindione
The serum concentration of Phenindione can be increased when it is combined with Lansoprazole.
Phenobarbital
The metabolism of Lansoprazole can be increased when combined with Phenobarbital.
Phenprocoumon
The serum concentration of Phenprocoumon can be increased when it is combined with Lansoprazole.
Phenytoin
The metabolism of Lansoprazole can be increased when combined with Phenytoin.
Pioglitazone
The metabolism of Lansoprazole can be decreased when combined with Pioglitazone.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Lansoprazole.
Posaconazole
The serum concentration of Posaconazole can be decreased when it is combined with Lansoprazole.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Lansoprazole.
Primidone
The metabolism of Lansoprazole can be increased when combined with Primidone.
Pyrimethamine
The metabolism of Lansoprazole can be decreased when combined with Pyrimethamine.
Quinine
The metabolism of Lansoprazole can be decreased when combined with Quinine.
Rabeprazole
The metabolism of Lansoprazole can be decreased when combined with Rabeprazole.
Raltegravir
The serum concentration of Raltegravir can be increased when it is combined with Lansoprazole.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Lansoprazole.
Rifabutin
The metabolism of Lansoprazole can be increased when combined with Rifabutin.
Rifampin
The metabolism of Lansoprazole can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Lansoprazole can be increased when combined with Rifapentine.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Lansoprazole.
Rilpivirine
The serum concentration of Rilpivirine can be decreased when it is combined with Lansoprazole.
Riociguat
The serum concentration of Riociguat can be decreased when it is combined with Lansoprazole.
Risedronate
The therapeutic efficacy of Risedronate can be decreased when used in combination with Lansoprazole.
Risedronic Acid
The therapeutic efficacy of Risedronate can be decreased when used in combination with Lansoprazole.
Rosiglitazone
The metabolism of Lansoprazole can be decreased when combined with Rosiglitazone.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Lansoprazole.
Rucaparib
The metabolism of Lansoprazole can be decreased when combined with Rucaparib.
Saquinavir
The serum concentration of Saquinavir can be increased when it is combined with Lansoprazole.
Saquinavir Mesylate
The serum concentration of Saquinavir can be increased when it is combined with Lansoprazole.
Sarilumab
The therapeutic efficacy of Lansoprazole can be decreased when used in combination with Sarilumab.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Lansoprazole.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Lansoprazole.
Secobarbital
The metabolism of Lansoprazole can be increased when combined with Secobarbital.
Sertraline
The metabolism of Lansoprazole can be decreased when combined with Sertraline.
Sildenafil
The metabolism of Lansoprazole can be decreased when combined with Sildenafil.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Lansoprazole.
Siltuximab
The serum concentration of Lansoprazole can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Lansoprazole can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Lansoprazole.
Sorafenib
The metabolism of Lansoprazole can be decreased when combined with Sorafenib.
ST. JOHN'S WORT EXTRACT
The serum concentration of Lansoprazole can be decreased when it is combined with St. John's Wort.
Sucroferric Oxyhydroxide
Lansoprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sulfadiazine
The metabolism of Lansoprazole can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Lansoprazole can be decreased when combined with Sulfamethoxazole.
Sulfisoxazole
The metabolism of Lansoprazole can be decreased when combined with Sulfisoxazole.
Tacrolimus
The serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole.
Tamoxifen
The metabolism of Lansoprazole can be decreased when combined with Tamoxifen.
Technetium Tc 99m Medronate
The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Lansoprazole.
Telaprevir
The metabolism of Lansoprazole can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Lansoprazole can be decreased when combined with Telithromycin.
Teriflunomide
The metabolism of Lansoprazole can be decreased when combined with Teriflunomide.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Lansoprazole.
Ticagrelor
The metabolism of Lansoprazole can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Lansoprazole can be decreased when combined with Ticlopidine.
Tiludronate
The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Lansoprazole.
Tiludronic Acid
The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Lansoprazole.
Tipranavir
The serum concentration of Lansoprazole can be decreased when it is combined with Tipranavir.
Tocilizumab
The serum concentration of Lansoprazole can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Lansoprazole can be decreased when combined with Tolbutamide.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Lansoprazole.
Topiramate
The metabolism of Lansoprazole can be decreased when combined with Topiramate.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Lansoprazole.
Tranylcypromine
The metabolism of Lansoprazole can be decreased when combined with Tranylcypromine.
Trimethoprim
The metabolism of Lansoprazole can be decreased when combined with Trimethoprim.
Valproate
The metabolism of Lansoprazole can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Lansoprazole can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Lansoprazole can be decreased when combined with Valsartan.
Vemurafenib
The serum concentration of Lansoprazole can be increased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Lansoprazole can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Lansoprazole can be decreased when combined with Verapamil.
Vincristine
The excretion of Vincristine can be decreased when combined with Lansoprazole.
Voriconazole
The serum concentration of Lansoprazole can be increased when it is combined with Voriconazole.
Warfarin
The serum concentration of Warfarin can be increased when it is combined with Lansoprazole.
Zafirlukast
The metabolism of Lansoprazole can be decreased when combined with Zafirlukast.
Ziprasidone
The metabolism of Lansoprazole can be decreased when combined with Ziprasidone.
Zoledronic Acid
The therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Lansoprazole.
Zoledronic Acid Anhydrous
The therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Lansoprazole.
